Assessment of Two Insulin Pump Insulin Delivery Systems in Type 1 Diabetes.

Christchurch Clinical Studies Trust Ltd60 enrolled

Overview

This is a study of the Minimed 670G 4.0 insulin pump, assessing the efficacy of the Advanced Hybrid Closed Loop (AHCL) algorithm in controlling blood glucose levels in Type 1 Diabetes.

Insulin delivery systems are an increasingly popular treatment option for Type I Diabetes (T1D). Delivery systems consist of an insulin pump, a glucose sensor with a transmitter attached, and a maths program (algorithm) built into the pump. The algorithm uses sensor glucose levels to decide how much insulin should be delivered by the pump. This study aims to see how well a new algorithm controls blood glucose levels in T1D. The study uses the MiniMed 670G 4.0 insulin pump and compares two different algorithms: 1. Advanced Hybrid Closed Loop (AHCL - the new algorithm) 2. Sensor augmented pump therapy with predictive low-glucose management (SAP with PLGM). Approximately 60 participants with T1D, aged 7 - 80 years, will take part in the study. Every participant will receive the following two treatment algorithms in random order, with a two-week washout between treatments: * MiniMed 670G 4.0 insulin pump in AHCL mode for 4 weeks. * MiniMed 670G 4.0 insulin pump in SAP + PLGM mode for 4 weeks. During the study insulin pump data will be uploaded and changes in health will be monitored. In addition, participants will complete 3-day food diaries and a number of questionnaires. Participants at the Dunedin site will also be asked to complete home sleep studies during the trial (optional). The results of the study will be used to further develop insulin delivery systems. It is hoped this may improve treatment for people with diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Type1diabetes

Interventions

AHCLDEVICE

Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.

SAP+PLGMDEVICE

Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.

Eligibility

Sex: ALLMin age: 7 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female aged 7 - 80 years inclusive. 2. Type I diabetes as per the American Diabetes Association Classification, diagnosed at least 1 year prior to Study Day 1. 3. On insulin pump therapy for at least 6 months prior to study Day 1. 4. Minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units. 5. Willing and able to adhere to the study protocol. 6. Access to the internet and a computer system that meets requirements for uploading the study pump. Exclusion Criteria: 1. Mean HbA1c more than 10.0% (86 mmol/mol) within 6 months prior to Study Day 1 (minimum of one test). 2. Use of a medication indicative of diabetes complications (ACE inhibitors and statins are permitted). 3. Use of systemic glucocorticoids within 2 weeks prior to the Baseline visit. 4. Current use of SGLT-2 or GLP-1 medications. 5. History or current evidence of significant seizure disorder, renal impairment or cardiovascular disease (including uncontrolled hypertension), in the opinion of the Investigator. 6. History of severe visual impairment, in the opinion of the Investigator. 7. If female, is pregnant or plans to become pregnant while participating in the study. A positive urine pregnancy test at Screening is exclusionary. 8. Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.

Locations (1)

Christchurch Clinical Studies Trust

Christchurch, Canterbury, New Zealand

RECRUITING

Outcomes

Primary Outcomes

Performance of the AHCL system

percentage of sensor glucose values between 3.9 - 10.0 mmol/L

Time frame: 4 weeks

Secondary Outcomes

Safety of the AHCL system

percentage of sensor glucose values \<3.9 mmol/L and \> 10 mmol/L

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.